Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q3 2026
Aurinia Pharmaceuticals (AUPH) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 30, 2026
Aurinia Pharmaceuticals (AUPH) reported revenue of $83.7M for the third quarter 2026 (Q3 2026), +14% from a year earlier and +0.6% from the quarter before. Operating margin was 42.3%, net earnings $31.7M (37.9% of revenue).
Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%, net earnings $31.7M, operating cash flow $46.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.7M | +0.6% | +14% |
| Operating profit | $35.4M | -24% | +19% |
| Net earnings | $31.7M | -15% | +0.5% |
| Operating cash flow | $46.4M | -12% | +4% |
What changed
Revenue was $83.7M in Q3 2026, up 14% year over year and up 1% from the previous quarter. Net product sales was the largest line at 95% of revenue. Net product sales added $8.8M year over year (up 12%), 86% of the total change.
Operating profit was $35.4M, a 42.3% margin (up 1.8 points year over year). Of the extra revenue versus Q3 2025, 55% reached operating profit, above the 40% margin then. Total costs grew 11% against revenue growth of 14%. Net earnings were $31.7M, roughly flat year over year. The effective tax rate was 18.1%.
Operating cash flow was $46.4M (up 4% year over year), 146% of net earnings. Non-cash charges added back $4.8M of depreciation and amortization and $6.1M of share-based compensation. Working capital and other items added $3.7M.
Questions
What was Aurinia Pharmaceuticals' revenue in the third quarter 2026?
Aurinia Pharmaceuticals (AUPH) reported revenue of $83.7M for the third quarter 2026 (Q3 2026), +14% from a year earlier and +0.6% from the quarter before.
Was Aurinia Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $35.4M (42.3% of revenue) and net earnings $31.7M.